Innovative personalized therapies targeting TREM-1 for life-threatening inflammatory syndromes such as septic shock

Inotrem is a French biopharmaceutical company founded in 2013, with offices in Paris and a technology center in Nancy (France).

Our mission is to improve public health by developing a new class of therapeutic solutions targeting the immunological pathway TREM-1 with a personalized medicine approach to manage life-threatening inflammatory syndromes with high unmet medical need. TREM-1 is a key amplifier of inflammatory responses implicated in various diseases such as septic shock, vaso-occlusive crisis in sickle cell disease, or hemorrhagic shock.

Our lead drug candidate nangibotide has shown promising results in Phase II trials for septic shock and severe COVID-19. Nangibotide is developed along with a proprietary Companion Diagnostic platform in partnership with Roche Diagnostics, to identify patients who would benefit most from our therapy. Nangibotide restores a balanced inflammatory response and improves outcomes particularly in patients with high levels of the soluble TREM-1 biomarker, a marker of TREM-1 activation. The regulatory path to registration in septic shock for nangibotide has been secured with major health authorities, and it has been granted EMA’s PRIority Medicine (PRIME) scheme, and Fast Track status by the FDA in that indication.